Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 1.09 [0.66, 1.79]
890 participants
Low
Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).
1 finding from 1 review
OR 0.71 [0.41, 1.23]
894 participants
Low
Adverse events · people aged 60 years and older living in the community
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people aged 60 years and older living in the community
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Adverse events · adults
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events · children (12 or over) and young adults with cystic fibrosis
It is very uncertain whether summary of findings: nitric oxide changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with COPD
1 finding from 1 review
Adverse events · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adult participants undergoing cardiac and major abdominal surgery
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention showed no clear difference in adverse events (low certainty).
1 finding from 1 review
Adverse events: number of people with 1 or more (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes adverse events: number of people with 1 or more (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events (Participants with one or more event) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review